Therapeutic Advances for Blocking Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva.
Br J Clin Pharmacol. 2018 Nov 30;:
Authors: Wentworth KL, Masharani U, Hsiao EC
Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease in which heterotopic bone forms in muscle and soft tissue, leading to joint dysfunction and significant disability. FOP is progressive and many patients are wheelchair-bound by the third decade of life. FOP is caused by an activating mutation in the ACVR1 gene, which encodes the activin A Type 1 receptor. Aberrant signaling through this receptor leads to over-activation of the pSMAD 1/5/9 pathway and triggers the formation of bone outside of the skeleton. There is no curative therapy for FOP; however, exciting advances in novel therapies have developed recently. Here, we review the clinical and translational pharmacology of three drugs that are currently in clinical trials (palovarotene, REGN 2477, and rapamycin) as well as other emerging treatment strategies for FOP.
PMID: 30501012 [PubMed – as supplied by publisher]